Special to UM News
Celebrating a significant 10-year milestone, Tallahassee resident Chris Schuh, 64, is grateful to be alive. Diagnosed with type 1 diabetes at age 30, Schuh received an islet cell transplant at the Diabetes Research Institute (DRI), and has been living free from insulin injections for a decade.
On February 11, Schuh met with her DRI doctors for a celebratory post-islet transplant follow-up. She joins other DRI transplant recipients who have been living insulin free, some for more than 10 years, demonstrating that natural insulin production can be restored in diabetes patients.
“The fact that it has worked so long is an incredible delight,” said Schuh. “To not worry about testing my blood sugar every time I walk out the door, or having to test 10 times a day, to not have to deal with the uncertainty of diabetes, it’s just plain old wonderful. I’m extremely grateful to be alive, and the only reason I am is because of the knowledge, care and expertise of the Diabetes Research Institute.”
Type 1 diabetes, also referred to as insulin-dependent diabetes, is an autoimmune disorder where the body’s immune system mistakenly sees the insulin-producing cells in the pancreas as foreign and destroys them.
The Diabetes Research Institute at the University of Miami Miller School of Medicine is the largest and most comprehensive research center dedicated to curing diabetes. A pioneer in islet cell transplantation, the DRI is aggressively working to develop a biological cure for all people affected by diabetes. To patients like Schuh, this life-changing procedure couldn’t have come soon enough.
“My body became resistant to insulin,” she said. “No matter how strict I was with what I ate, or how detailed I was with the records I kept, it didn’t matter. My blood sugar numbers were always high, which is poison to your system.”
Now retired, Schuh spent her career as an executive of a statewide Florida association that required traveling – something that was too dangerous to do on her own.
“I couldn’t travel alone,” she said. “Stress makes your blood sugar go low, taking too much insulin makes you go low, activity can cause you to go low – I would never know when that was going to happen.”
A low blood sugar, also known as hypoglycemia, can be a dangerous condition that can cause fainting, seizure, coma or even death.
Worried that she wouldn’t live to see the age of 50 or even see her daughter off to college, Schuh found a glimmer of hope when she read a small item in the newspaper that was calling for clinical trial patient applications.
“That little three-inch column in the paper helped change my life!” she said.
After checking with her endocrinologist, Schuh applied to be a candidate for the DRI’s islet transplantation clinical trials. Following an intense screening process, she was accepted as a participant and was called for her first infusion of insulin-producing cells.
Although she lived decades of being on a rigid schedule of eating at specific times, which was always matched with insulin intake, Schuh remembered a feeling she had never really felt before shortly after the transplant.
“I finally felt hungry,” she said. “Something as simple as eating food became a whole new experience.”
Schuh was insulin-free for a short time following the first transplant but needed another infusion of cells. Since that second transplant, she has been free of insulin injections for 10 years, which is a significant benchmark.
“I feel alive and vibrant,” Schuh said. “Nothing is holding me back. I’ve taken master gardening classes. I rode a mule into the Grand Canyon. I’ve traveled the world without worry. I swam with dolphins.”
Schuh had never thought she would make it past 50, due to the severity of her diabetes and hypoglycemic reactions.
“One thing I want parents, kids, and all others affected by diabetes to know is that the cure is coming. Do not dismay. It will happen in our lifetime,” said Schuh, who firmly believes in and supports the Diabetes Research Institute’s singular mission – to find a biological cure for diabetes.
Building on these promising outcomes, the DRI is developing the DRI BioHub, a bioengineered “mini organ” that mimics the native pancreas. While various BioHub platforms are being tested in preclinical and clinical studies, the DRI is also developing strategies to eliminate the need for anti-rejection drugs and reset the immune system to block autoimmunity.
To learn more about clinical trials or the work of the Diabetes Research Institute, call 1-800-321-3437 or visit the DRI website.